Dr. Rubin highlights a new subcutaneous induction for UC, stressing convenience, access, and sustained remission.
Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...
The tennis star looked happy and slender in the skimpy baby blue lace-trimmed outfit that made the most of her slender legs.
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
Investor's Business Daily on MSN
Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff
The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner Merck (MSD) in the U.S.
A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback